Overview An Open Label Study of Severe Sepsis in Adults Status: Completed Trial end date: 2003-10-01 Target enrollment: Participant gender: Summary This trial is to obtain safety data in adult patients with severe sepsis and two sepsis-induced organ infections who receive an infusion of drotrecogin alfa (activated). Phase: Phase 4 Details Lead Sponsor: Eli Lilly and CompanyTreatments: Drotrecogin alfa activatedProtein C